Medical device manufacturers making cosmetic / aesthetic products.
Breast implant maker Sientra raised the upper limit on its planned initial public offering of stock to $92 million, after filing in mid-September for an $86 million IPO.
Breast implant maker Sientra set a price range for its planned initial public offering and raised the upper limit to $92 million, after filing in mid-September for an $86 million IPO.
Medical aesthetics company Sientra files registration documents for an initial public offering proposed to raise as much as $86.3 million.
California medical device maker Sientra Inc. is looking to hit the public markets with an initial public offering that could raise as much as $86.3 million, according to an SEC filing.
California-based Allergan informs state regulators that it plans to permanently lay off 129 employees.
Embattled aesthetic devices maker Allergan (NYSE:AGN) informed California state authorities that it plans to cut 129 workers over the next few weeks.
Cynosure rounds out its minimally and non-invasive aesthetics portfolio with the $13.2 million acquisition of Ellman Intl. and its radiofrequency devices.
Massachusetts-based Cynosure (NSDQ:CYNO) is looking to expand its market with new radiofrequency-based devices picked up in its $13.2 million acquisition of Ellman Intl.
Botox-maker Allergan acquiesces to Valeant Pharmaceuticals' demands for a special shareholder meeting, but takes to court to prevent Valeant and its compatriots from voting their shares.
The FTC issued a "Second Request" for more information about Valeant Pharmaceuticals' ongoing attempts to take over Allergan.
Federal authorities are taking a closer look at Allergan's (NYSE:AGN) ongoing battle to keep unrequited acquirer Valeant Pharmaceuticals at bay.
Allergan uses the occasion of unrequited buyer Valeant Pharmaceuticals' latest financial report to drive home allegations that Valeant isn't being upfront about its business and accounting practices.